183 related articles for article (PubMed ID: 29341162)
1. Impact of genomics on the surgical management of melanoma.
Ferguson PM; Long GV; Scolyer RA; Thompson JF
Br J Surg; 2018 Jan; 105(2):e31-e47. PubMed ID: 29341162
[TBL] [Abstract][Full Text] [Related]
2. Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma.
Olszanski AJ
J Natl Compr Canc Netw; 2019 May; 17(5.5):615-617. PubMed ID: 31117032
[TBL] [Abstract][Full Text] [Related]
3. Emerging Biomarkers in Cutaneous Melanoma.
Eisenstein A; Gonzalez EC; Raghunathan R; Xu X; Wu M; McLean EO; McGee J; Ryu B; Alani RM
Mol Diagn Ther; 2018 Apr; 22(2):203-218. PubMed ID: 29411301
[TBL] [Abstract][Full Text] [Related]
4. [Molecular diagnostics in melanoma].
Lang R; Bauer JW; Laimer M
Hautarzt; 2015 Apr; 66(4):277-81. PubMed ID: 25783213
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in melanoma.
Griewank KG
Scand J Clin Lab Invest Suppl; 2016; 245():S104-12. PubMed ID: 27467728
[TBL] [Abstract][Full Text] [Related]
6. Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.
Chapman PB; Hauschild A; Sondak VK
Am Soc Clin Oncol Educ Book; 2014; ():e412-21. PubMed ID: 24857132
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
8. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
[TBL] [Abstract][Full Text] [Related]
9. Dermoscopy in the era of dermato-oncology: from bed to bench side and retour.
Woltsche N; Schwab C; Deinlein T; Hofmann-Wellenhof R; Zalaudek I
Expert Rev Anticancer Ther; 2016 May; 16(5):531-41. PubMed ID: 26999650
[TBL] [Abstract][Full Text] [Related]
10. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
11. Fifty years of progress in surgical oncology: Melanoma.
Coit DG; Ariyan CE
J Surg Oncol; 2022 Oct; 126(5):888-895. PubMed ID: 36087090
[TBL] [Abstract][Full Text] [Related]
12. Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA.
Oldenburg RP; Liu MS; Kolodney MS
J Invest Dermatol; 2008 Feb; 128(2):398-402. PubMed ID: 17581615
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling in melanoma: past results and future potential.
Knackstedt RW; Knackstedt T; Gastman B
Future Oncol; 2019 Mar; 15(7):791-800. PubMed ID: 30453756
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data.
Lu X; Zhang Q; Wang Y; Zhang L; Zhao H; Chen C; Wang Y; Liu S; Lu T; Wang F; Yan F
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1635-1647. PubMed ID: 29948145
[TBL] [Abstract][Full Text] [Related]
16. Surgical management of metastatic melanoma in the era of targeted systemic therapies.
O'Leary DP; Byrnes KG; Power DG; Redmond HP
Melanoma Res; 2015 Feb; 25(1):1-8. PubMed ID: 25532830
[TBL] [Abstract][Full Text] [Related]
17. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
19. [Molecular and immunohistochemical diagnostics in melanoma].
Schilling B; Griewank KG
Hautarzt; 2016 Jul; 67(7):511-8. PubMed ID: 27270408
[TBL] [Abstract][Full Text] [Related]
20. Molecular testing in melanoma.
Wilson MA; Nathanson KL
Cancer J; 2012; 18(2):117-23. PubMed ID: 22453011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
